We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Just over a year since its IPO, Athenex is broadening its scope—the biotech is picking up a $100 million investment from Perceptive Advisors, licensing a modified cancer-fighting enzyme and launching a new Chinese joint venture built around T-cell recepto